Nxera seeks schizophrenia programme buyer after Boehringer snub
Shares in Tokyo-listed Nxera Pharma slid 5% at market open after Boehringer walked away from the neurological assets.
Neurology
Sanofi shares fall 6% after double setback for MS drug tolebrutinib
High-dose Spinraza inches closer to EU approval despite FDA setback
Modulight secures $12m to shine precise light on neurological diseases
J&J’s Caplyta wins MDD approval to extend revenue horizon
Roche bids to broaden MS pipeline and strengthen Ocrevus influence
FDA delays approval decision for Sanofi’s MS treatment tolebrutinib
Reunion Neuroscience expands Series A to $133m after positive trial milestones
